EQUITY RESEARCH – RESULTS FLASH

SRIVICHAIVEJVIVAT



3Q24 results at first glance

Core profit grew by 8% y-y to THB93m in 3Q24

Highlights

- VIH reported a core profit of THB93m in 3Q24 (+8% y-y, +20% q-q).
- In this quarter, VIH booked a SSO revenue reversal of THB14.5m following the insufficient budget for high-cost care (RW>=2), which was revised down to THB7,200/RW from THB12,000/RW for the treatments during Oct to Dec-23. Excluding this item, VIH's core profit would be THB104m (+20% y-y).
- Hospital revenue was flat y-y in 3Q24. Revenue from self-pay patients grew by 1% y-y. Revenue from SSO patients grew by 1% yy thanks to a higher number of registered insurers. Excluding the SSO revenue reversal, total revenue and SSO revenue would grow by 3% y-y and 10% y-y, respectively.
- COGS increased by only 1% y-y due to efficient cost management. SG&A decreased by 3% y-y. As a result, the 3Q24 EBITDA margin improve to 22.2% (vs 21.2% in 3Q23). Excluding the SSO revenue reversal, the EBITDA margin would improve to 23.7%.
- 9M24 core profit grew by 29% y-y to THB242m and accounted for 71% of our 2024 core profit forecast of THB340m.

Outlook

- We expect the strong earnings growth momentum to continue in 4Q24, driven by medical fee adjustments by 3-7%, effective in October.
- VIH trades at a cheap valuation of only 16x 2025E P/E (vs peers' average of 24x).

TARGET PRICE THB15.00 CLOSE THB10.20 UP/DOWNSIDE +47.1% TP vs CONSENSUS +0.0%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	2,734	2,969	3,168	3,435
Net profit	284	340	388	361
EPS (THB)	0.50	0.56	0.64	0.59
vs Consensus (%)	-	3.7	3.2	1.7
EBITDA	539	605	666	697
Recurring net profit	284	340	388	361
Core EPS (THB)	0.50	0.54	0.62	0.58
EPS growth (%)	(59.2)	8.8	14.3	(7.0)
Core P/E (x)	20.5	18.9	16.5	17.7
Dividend yield (%)	2.0	2.2	2.5	2.3
EV/EBITDA (x)	9.5	8.2	9.5	9.7
Price/book (x)	1.9	1.7	1.6	1.5
Net debt/Equity (%)	(22.9)	(35.2)	2.2	8.4
ROE (%)	9.4	10.3	10.5	9.1



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	12.1	1.0	36.0
Relative to country (%)	14.0	(9.4)	30.8
Mkt cap (USD m)			181
3m avg. daily turnover (USD m)			0.2
Free float (%)			33
Major shareholder		BBTV Ec	uity (19%)
12m high/low (THB)			11.90/7.00
Issued shares (m)			627.73

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

VIH TB

Exhibit 1: VIH – 3Q24 results summary

	3Q23	4Q23	1Q24	2Q24	3Q24	Cha	nge	2023	2024E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Revenue	733	769	665	679	734	8	0	2,734	2,969	9
Cost of sales (Incl. depreciation)	(545)	(552)	(502)	(514)	(548)	6	1	(2,062)	(2,228)	8
Gross profit	188	217	163	165	186	13	(1)	671	741	10
SG&A	(82)	(100)	(80)	(79)	(80)	1	(3)	(337)	(350)	4
Operating profit	106	117	83	86	106	24	0	335	391	17
Other operating income	5	9	8	8	11			3	3	4
Dividend income	0	0	0	3	0			27	32	20
Equity income	0	0	0	0	0			-	-	
EBIT	111	126	91	97	118	22	6	364	426	17
Interest expense	(2)	(2)	(2)	(1)	(1)	7	(40)	(10)	(5)	(47)
EBT	108	124	89	95	116	22	7	354	421	19
Income tax	(22)	(24)	(17)	(18)	(23)	31	4	(69)	(80)	16
Minority interests	(0)	(0)	(0)	(0)	(0)	7	4	(1)	(1)	
Core profit	86	99	72	77	93	20	8	284	340	20
Extraordinaries										
Net income	86	99	72	77	93	20	8	284	340	20
Core EPS (THB)	0.15	0.17	0.13	0.12	0.15	20	(2)	0.50	0.54	9
No of share (m)	571	571	571	628	628	0	10	571	628	10
Cost (Excl. depreciation)	(500)	(508)	(458)	(470)	(502)	7	0	(1,887)	(2,049)	9
Depreciation & amortisation	(45)	(44)	(44)	(44)	(45)	4	2	(175)	(179)	2
EBITDA	155	170	135	140	163	16	5	539	605	12
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	26	28	25	24	25	1	(0)	25	25	0
SG&A/Revenue	11	13	12	12	11	(1)	(0)	12	12	(1)
EBITDA margin	21.2	22.1	20.3	20.7	22.2	2	1	20	20	1
Net profit margin	12	13	11	11	13	1	1	10	11	1
Operating stats	(y-y %)	(y-y %)	(у-у %)	(y-y %)	(y-y %)					
Self pay patient revenue growth	-	-	11	9	10					
Self pay patient OPD revenue growth	-	-	-	-	-					
Self pay patient IPD revenue growth	-	-	-	-	-					
SSO revenue growth	-	-	7	6	2					
SSO registered members ('000)	-	-	210	211	-					
SSO revenue per head	-	-	2,926	3,003	-					

Sources: VIH; FSSIA estimates

Financial Statements

Srivichaivejvivat

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	3,646	2,734	2,969	3,168	3,435
Cost of goods sold	(2,362)	(2,062)	(2,228)	(2,355)	(2,549)
Gross profit	1,284	671	741	814	886
Other operating income	16	29	35	36	37
Operating costs	(417)	(337)	(350)	(368)	(435)
Operating EBITDA	1,053	539	605	666	697
Depreciation	(170)	(175)	(179)	(184)	(210)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	883	364	426	482	487
Net financing costs	(11)	(10)	(5)	(1)	(21)
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	0	0	0	0	0
Profit before tax	872	354	421	481	467
Тах	(173)	(69)	(80)	(91)	(105)
Profit after tax	699	285	341	389	362
Minority interests	(3)	(1)	(1)	(1)	(1)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	697	284	340	388	361
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	697	284	340	388	361
Per share (THB)					
Recurring EPS *	1.22	0.50	0.54	0.62	0.58
Reported EPS	1.22	0.50	0.56	0.64	0.59
DPS	0.45	0.20	0.22	0.26	0.24
Diluted shares (used to calculate per share data)	571	571	628	628	628
Growth					
Revenue (%)	(22.7)	(25.0)	8.6	6.7	8.4
Operating EBITDA (%)	(40.3)	(48.8)	12.1	10.2	4.7
Operating EBIT (%)	(45.0)	(58.8)	17.0	13.2	1.1
Recurring EPS (%)	(44.5)	(59.2)	8.8	14.3	(7.0)
Reported EPS (%)	(44.5)	(59.2)	12.2	14.3	(7.0)
Operating performance					
Gross margin inc. depreciation (%)	35.2	24.6	25.0	25.7	25.8
Gross margin exc. depreciation (%)	39.9	31.0	31.0	31.5	31.9
Operating EBITDA margin (%)	28.9	19.7	20.4	21.0	20.3
Operating EBIT margin (%)	24.2	13.3	14.3	15.2	14.2
Net margin (%)	19.1	10.4	11.4	12.3	10.5
Effective tax rate (%)	19.8	19.5	19.0	19.0	22.4
Dividend payout on recurring profit (%)	36.9	40.2	41.3	41.3	41.3
Interest cover (X)	80.2	36.8	80.9	385.6	23.6
Inventory days	10.2	11.4	10.7	10.8	10.7
Debtor days	55.3	60.6	60.6	58.5	53.9
Creditor days	71.4	70.7	66.0	66.8	66.3
Operating ROIC (%)	37.0	13.2	14.9	12.6	9.0
ROIC (%)	35.4	12.7	14.4	12.3	8.8
ROE (%)	24.9	9.4	10.3	10.5	9.1
ROA (%) * Pre exceptional, pre-goodwill and fully diluted	19.3	8.0	8.9	8.5	6.7
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Self pay patient revenue	3,106	2,126	2,349	2,530	2,777
		1			,

Sources: Srivichaivejvivat; FSSIA estimates

Financial Statements Srivichaivejvivat

Srivichaivejvivat					
Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	697	284	340	388	361
Depreciation	170	175	179	184	210
Associates & minorities	-	-	-	-	-
Other non-cash items	(2)	(1)	1	1	1
Change in working capital	71	(97)	(2)	21	29
Cash flow from operations Capex - maintenance	936 (648)	361 (284)	517 (148)	594 (1,793)	601 (867)
Capex - maintenance Capex - new investment	(040)	(204)	(140)	(1,793)	(007)
Net acquisitions & disposals	0	0	0	0	0
Other investments (net)	-	-	-	-	-
Cash flow from investing	(648)	(284)	(148)	(1,793)	(867)
Dividends paid	(285)	(257)	(114)	(136)	(155)
Equity finance	0	0	303	0	152
Debt finance	(123)	(61)	(75)	700	750
Other financing cash flows	(1)	0	(1)	(1)	(1)
Cash flow from financing	(410)	(318)	112	563	746
Non-recurring cash flows Other adjustments	- 0	-	- 0	- 0	- 0
Net other adjustments	0	0	0	0	0
Movement in cash	(122)	(241)	481	(636)	480
Free cash flow to firm (FCFF)	298.63	86.97	374.05	(1,197.73)	(245.23)
Free cash flow to equity (FCFE)	163.04	16.67	292.24	(500.16)	482.85
Per share (THB)					
CFF per share	0.48	0.14	0.60	(1.91)	(0.39)
FCFE per share	0.48	0.03	0.00	(0.80)	(0.39)
Recurring cash flow per share	1.52	0.80	0.85	0.94	0.94
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Fangible fixed assets (gross)	3,760	3,975	4,123	5,917	6,784
Less: Accumulated depreciation	(1,705)	(1,811)	(1,990)	(2,174)	(2,384)
Fangible fixed assets (net)	2,055	2,164	2,134	3,743	4,400
ntangible fixed assets (net)	0	0	0	0	0
ong-term financial assets	-	-	-	-	-
nvest. in associates & subsidiaries	0	0	0	0	0
Cash & equivalents	1,063	822	1,304	667	1,147
VC receivable	429	478	507	507	507
nventories	61	57	62	66	71 14
Other current assets Current assets	11 1,564	11 1,368	12 1,885	12 1,253	1,739
Other assets	88	87	87	87	87
Total assets	3,708	3,619	4,105	5,083	6,226
Common equity	3,001	3,029	3,558	3,810	4,168
Minorities etc.	7	8	8	8	8
Fotal shareholders' equity	3,008	3,037	3,565	3,818	4,176
_ong term debt	186	125	50	750	1,500
Other long-term liabilities	74	70	70	70	70
Long-term liabilities	260	195	120	820	1,570
VC payable Short term debt	376 0	355 0	386 0	409 0	441 0
Difference of the second se	64	32	34	37	0 40
Current liabilities	439	387	420	445	40 480
Fotal liabilities and shareholders' equity	3,708	3,619	4,105	5,083	6,226
Net working capital	62	159	161	141	112
nvested capital	2,205	2,410	2,381	3,970	4,598
Includes convertibles and preferred stock which is being	treated as debt				
Per share (THB)					
Book value per share	5.26	5.31	5.84	6.26	6.64
Fangible book value per share	5.26	5.31	5.84	6.26	6.64
Financial strength					
Net debt/equity (%)	(29.1)	(22.9)	(35.2)	2.2	8.4
Net debt/total assets (%)	(23.6)	(19.3)	(30.5)	1.6	5.7
Current ratio (x)	3.6 15.8	3.5	4.5	2.8	3.6 24.4
CF interest cover (x)	15.8	2.7	56.5	(399.1)	24.4
aluation	2022	2023	2024E	2025E	2026E
	8.4	20.5	18.9	16.5	17.7
- ()	-	30.2	27.7	24.3	26.1
Recurring P/E @ target price (x) *	12.3		10 -		
Recurring P/E @ target price (x) * Reported P/E (x)	8.4	20.5	18.3	16.0	17.2
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%)	8.4 4.4	20.5 2.0	2.2	2.5	2.3
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x)	8.4 4.4 1.9	20.5 2.0 1.9	2.2 1.7	2.5 1.6	2.3 1.5
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	8.4 4.4 1.9 1.9	20.5 2.0 1.9 1.9	2.2 1.7 1.7	2.5 1.6 1.6	2.3 1.5 1.5
Recurring P/E (x) * Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x) EV/EBITDA (x) ** EV/EBITDA @ target price (x) **	8.4 4.4 1.9 1.9 4.7	20.5 2.0 1.9 1.9 9.5	2.2 1.7 1.7 8.2	2.5 1.6 1.6 9.5	2.3 1.5 1.5 9.7
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	8.4 4.4 1.9 1.9	20.5 2.0 1.9 1.9	2.2 1.7 1.7	2.5 1.6 1.6	2.3 1.5 1.5

Sources: Srivichaivejvivat; FSSIA estimates



Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating					
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process base from the ann Only the top- inclusion.	ed on the com ual S&P Glob -ranked compa	transparent, rules-basec panies' Total Sustainabi al Corporate Sustainabil anies within each industr	ility Scores resulting ity Assessment (CSA). ry are selected for	Sustainability A ESG Score of I scoring compar selected from t	ssessment (C ess than 45% ny are disqual ne Eligible Un		ompanies with al ESG Score uents of the D	an S&P Globa of the highest JSI indices are	
Sustainability Investment List (<u>THSI</u>) by The Stock Exchange of Thailand (<u>SET</u>)	managing bu Candidates r 1) no irregula float of >150 up capital. So 70%; 2) inde wrongdoing r	usiness with tra must pass the ar trading of th shareholders ome key disqu pendent direc related to CG,	lity in Environmental and ansparency in Governar preemptive criteria, with le board members and e , and combined holding Jalifying criteria include: tors and free float violati social & environmental arnings in red for > 3 ye	ace, updated annually. a two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJS during the assessment year. The scoring will be fairly weighted against t nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (~USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight maximum, and no cap for number of stocks.					
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	he Thai IOD,	h in sustainable develop with support from the Sto ts are from the perspecti s.	ock Exchange of	Good (80-89), 3 and not rated fo equitable treatr	3 for Good (70 or scores belo nent of shareh (5%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (f w 50. Weightings nolders (weight 2 osure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), e rights; 2) and); 3) the role of	
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of su exercised. The and verifiability	e incorporated and sufficiently e CG compon r AGM proced and after the r ufficient informai s second assess r; and 3) openne	which shareholders' right I into business operation y disclosed. All form imp ents to be evaluated anr ures before the meeting meeting (10%). (The first a tion for voting; and 2) facilita es 1) the ease of attending ress for Q&A. The third involve es, resolutions and voting re	is and information is ortant elements of two nually. The assessment (45%), at the meeting assesses 1) advance ting how voting rights can be meetings; 2) transparency es the meeting minutes that	two ment ting <i>can be</i> <i>ncy</i>					
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies de Declaration of Certification, in managers and	nt of key contro Certification i eciding to becom Intent to kick off ocluding risk asso	Checklist include corrupt ols, and the monitoring a is good for three years. <i>ne a CAC certified member s an 18-month deadline to su</i> <i>essment, in place of policy a</i> <i>ablishment of whistleblowing</i> <i>II stakeholders.</i>)	and developing of start by submitting a bmit the CAC Checklist for ind control, training of	passed Checkli	st will move for se members a	ed by a committe or granting certific re twelve highly i ichievements.	cation by the 0	CAC Council	
<u>Morningstar</u> <u>Sustainalytics</u>	based on an risk is unmar regulatory filing	Sustainalytics' ESG risk rating provides an overall company score I on an assessment of how much of a company's exposure to ESG unmanaged. Sources to be reviewed include corporate publications and tory filings, news and other media, NGO reports/websites, multi-sector			managed, the	score is the sum higher ESG risk	is scored.			
		mpany feedbaci Jality & peer revi	k, ESG controversies, issuer iews.	feedback on draft ESG	0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+	
ESG Book	positioned to the principle helps explair over-weightir	outperform of financial manual financial manual financial manual fitter of the second se	sustainable companies th ver the long term. The rr ateriality including inform djusted performance. Ma th higher materiality and rly basis.	nethodology considers nation that significantly ateriality is applied by	The total ESG scores using m	score is calcul ateriality-base	ated as a weight d weights. The s ndicating better p	ed sum of the core is scaled		
<u>MSCI</u>				anagement of financially their exposure to ESG ri					ethodology to	
	AAA AA	8.571-10.000	Leader:	leading its industry in m	nanaging the most si	gnificant ESG ri	sks and opportunitie	es		
	A BBB BB	4.286-5.713	 5.714-7.142 4.286-5.713 Average: a mixed or unexceptional track record of managing the most significant ESG risks and opportunities relative to industry peers 2.857-4.285 						nities relative to	
	B CCC	1.429-2.856 0.000-1.428	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manage significar	nt ESG risks		
<u>Moody's ESG</u> solutions	believes that	esses the deg a company in	ree to which companies	take into account ESG o nto its business model an medium to long term.						
<u>Refinitiv ESG</u> rating	based on pu	blicly available	e and auditable data. Th	e a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performar	nce and insufficie	nt degree of t		
S&P Global				asuring a company's perf ssification. The score ran			of ESG risks, op	portunities, an	d impacts	
				lating the company's agg	regated Environn	nental, Social	and Governance	(ESG) perfor	mance The	
Bloomberg	ESG Score			mberg's view of ESG fination the weights are determined and the set of the se	ancial materiality.	The score is	a weighted gene	ralized mean (power mean)	

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

FINANSIA

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Teerapol Udomvej, CFA started covering this stock from 22-Oct-2024

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Srivichaivejvivat	VIH TB	THB 10.20	BUY	Downside risks to our DCF-based target price include 1) a slowdown in Thai patient volume due to economic slowdown; 2) regulatory risks from drug price and medical bill controls; and 3) SSO provision expenses following limited budgets from the SSO.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 12-Nov-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

